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Orally administered anti-retroviral drugs show considerable promise for HIV/AIDS pre-exposure pro-
phylaxis (PrEP). For the success of these strategies, pharmacokinetic (PK) data deﬁning the optimal
concentration of the drug needed for protection in relevant mucosal exposure sites is essential. Here we
employed a humanized mouse model to derive comprehensive PK data on the HIV integrase inhibitor
raltegravir (RAL), a leading PrEP drug candidate. Under steady state conditions following oral dosing,
plasma and multiple mucosal tissues were sampled simultaneously. RAL exhibited higher drug exposure
in mucosal tissues relative to that in plasma with one log higher exposure in vaginal and rectal tissue and
two logs higher exposure in intestinal mucosa reﬂecting the trends seen in the human studies. These
data demonstrate the suitability of RAL for HIV PrEP and validate the utility of humanized mouse models
for deriving important preclinical PK–PD data.
& 2015 Elsevier Inc. All rights reserved.Introduction
In the absence of an effective vaccine, other practical preventative
approaches are needed to contain the unrelenting HIV-1 pandemic.
While condom use is effective in reducing the viral transmission, non-
compliance is a signiﬁcant issue. Pre-exposure prophylactic strategies
that encompass either topical use of microbicides or oral administra-
tion of anti-HIV-1 drugs are now among the important avenues for
HIV-1 prevention. Although a number of antiretroviral therapeutic
compounds (ARTs) have been investigated in recent years for HIV-1
prevention, only one prescription drug Truvada that consists of a
combination of two RT inhibitors Tenofovir and Emtricitabine has
been licensed clinically thus far. While protection was shown in stu-
dies involving HIV-discordant couples, men having sex with men
(MSM) and heterosexual population, it is not complete however
(Grant et al., 2010; Baeten et al., 2012; Thigpen et al., 2012). Thus, there
is a constant need to identify and conduct preclinical testing of new
compounds for HIV-1 prevention (Burns et al., 2014).
A commonly used strategy for developing PrEP agents is to test
the currently available anti-HIV-1 therapeutic drugs (Burns et al.,2014; Trezza and Kashuba, 2014). While this approach is rational, a
major obstacle has been in deﬁning the optimal preventive doses
of these antiretrovirals which were originally formulated to reduce
the viral loads to undetectable levels as measured in the periph-
eral blood. For prevention however, a different dose of the drug
might be necessary to reach effective exposure (concentration) in
the vaginal and rectal mucosa wherein the initial infection takes
hold (Burgener et al., 2015). Therefore, a major task in the PrEP
ﬁeld is to evaluate the capacity for mucosal accumulation of var-
ious ARTs to ascertain their potential application for long-term
preventive use (Burns et al., 2014; Trezza and Kashuba, 2014).
In this regard, animal models that mimic HIV-1 transmission
via mucosal routes are of importance to deﬁne PK–PD relation-
ships of various drugs currently in the pipeline. Preclinical data
generated using animal models will form a baseline and better
inform in the design of future clinical trials in the human. In this
context, a number of early studies using non-human primate
(NHP) models have yielded critical data and set the stage for many
previous ﬁeld trials (reviewed in García-Lerma and Heneine
(2012)). However, the use of NHP models is often not cost-effective
and NHP protective studies are done in the context of SIV/SHIV
and not HIV-1 infection. Some of these drawbacks are overcome
by the use of humanized mouse models that permit HIV-1
mucosal transmission via vaginal and rectal routes (Karpel et al.,
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encompass hu-HSC and BLT mouse models are currently used.
Indeed, several ARTs have been successfully tested in these hu-
mouse models to determine their in vivo efﬁcacy against HIV-1
transmission (Chateau et al., 2013; Choudhary et al., 2009; Denton
et al., 2010, 2008, 2011; Neff et al., 2011, 2010). These ARTs include
tenofovir, emtricitabine, maraviroc and raltegravir (RAL) that act
via different mechanisms on various viral and cellular targets.
Of these, RAL is a ﬁrst generation HIV-1 integrase strand
transfer inhibitor, which is approved for clinical use in adult and
adolescent patients as well as in children. It is effective against
multiple wild-type and drug resistant HIV-1 clinical isolates and
against both CCR5 and CXCR4 tropic HIV-1 (Summa et al., 2008).
Its mode of action makes RAL an optimal complement to reverse
transcriptase (RT) inhibitors. Low molecular weight, lipophilicity
and high protein binding indicate good potential for penetration
into tissues following oral application (Iwamoto et al., 2008). Other
favorable aspects of RAL include mild side effects and minimal
drug-drug interactions (Summa et al., 2008; Nguyen et al., 2011;
Kassahun et al., 2007). Moreover, the binding of RAL to the HIV-1
pre-integration complex (PIC) is considered to be irreversible thus
having a durable anti-viral effect (Grobler et al., 2009; Hightower
et al., 2011). The outlined characteristics make RAL a promising
candidate for PrEP against HIV-1 mucosal transmission.
For its successful deployment as a PrEP drug in the ﬁeld,
detailed PK studies are needed in the context of RAL mucosal drug
accumulation and retention. While a number of recent studies on
human volunteers have yielded important information on mucosal
drug distribution (Clavel et al., 2011; Patterson et al., 2010, 2013),
controlled experimental studies that address the drug distribution
simultaneously in all the relevant body compartments namely,
plasma, vaginal, rectal and intestinal tissues have not been possi-
ble due to the impracticality of obtaining human biopsies at dif-
ferent times from numerous tissues. This difﬁculty can be over-
come with PrEP PK studies conducted in animal models (Veseli-
novic et al., 2014).
We have previously shown that hu-mice treated with human
equivalent doses of RAL by oral dosing were fully protected against
HIV-1 vaginal challenge (Neff et al., 2010). However, detailed PK
studies have been lacking. Therefore, here we evaluated the PK
aspects of RAL in various body compartments that encompass
plasma, vaginal, rectal and intestinal tissues to determine the
differential distribution and accumulation of the drug and com-
pared the values with those of in the human. Our results showed
that the overall PK trends seen in hu-mice reﬂect those seen in
human studies thus highlighting the value of using this model for
preclinical PK studies.Results
RAL concentrations in plasma and mucosal tissues of humanized mice
Composite data on RAL concentrations for all mice in plasma
and tissue compartments are presented in Fig. 1A, whereas data
for individual mice (5–8 mice per time point) for each of the
compartments at different time points are presented in Fig. 1B–E.
RAL was readily detectable at each of the time points analyzed.
The median composite PK proﬁles showed that highest RAL con-
centrations were detected at 2 h (Tmax) for all matrices (Fig. 1). This
was followed by a gradual decline in RAL concentrations in tissues
and plasma by 24 h and 48 h, respectively, and no detectable drug
in some mice at these time points (Fig. 1). Variability was observed
in RAL concentration among different mice within the same
compartment and time point analyzed, as depicted by coefﬁcients
of variation (CV%) (Supplemental Table 1).Pharmacokinetic parameters of raltegravir in plasma and mucosal
tissue compartments
Pharmacokinetic data are presented in Table 1. The cumulative
composite drug exposures reﬂected by AUC24h, median Cmax and
Ctrough, were higher in all tissue compartments compared to
plasma. Relative to plasma, Cmax values were 12 and 4 fold higher
in vaginal and rectal tissues, with RAL Cmax concentrations in
intestinal tissues being the highest (40 fold compared to plasma).
The Ctrough values were similar in plasma and vaginal tissue
(3.6 ng/ml and 3.2 ng/g) whereas they were higher in rectal
(5.5 ng/g) and even higher (5 fold compared to plasma) in
intestinal tissue. Exposure of RAL, measured as AUC was the
highest in the intestinal tissue (AUC24h: 135,610 ng/gh) and was
one log higher than in vaginal tissue (AUC24h: 28,172 ng/gh).
Exposure in the intestinal tissue was also one log higher than in
rectal tissue (AUC24h: 39,742 ng/gh). All tissues showed higher
exposure compared to plasma, with the AUC48h of 5510 ng/mlh.
The signiﬁcantly higher exposure in the tissues was further con-
ﬁrmed by the AUC24h tissue:plasma ratios. The AUC24h tissue:
plasma ratio was 6 in vaginal tissue, 8.5 in rectal tissue and 29 in
the intestines, (Fig. 2). Similar elimination rate was seen in all
compartments, with RAL half-life of 3.5 h, 3.3 h, 3.5 h and 2.8 h in
plasma, vaginal, rectal and intestinal tissue, respectively.Discussion
Many clinical trials are underway in the area of HIV-1 PrEP with
a number of ART drugs previously approved for therapeutic pur-
poses (Burns et al., 2014; Trezza and Kashuba, 2014). However, the
dosages used for the suppression of viral loads may not represent
doses necessary to confer full protection against HIV-1. Thus, the
optimal protective drug concentrations at the common mucosal
viral entry sites such as vaginal and rectal tissue need to be
established to deﬁne accurate dosing. In this regard, exploitation
of animal models that permit evaluation of important PK–PD
parameters would help provide critical preclinical data (Veseli-
novic et al., 2014).
Here we utilized a hu-HSC-Rag humanized mouse model sus-
ceptible to HIV-1 mucosal transmission to measure RAL con-
centrations in vivo and deﬁne various PK parameters following
oral dosing with RAL. While there were a number of previous
studies in the human (Burns et al., 2014; Trezza and Kashuba,
2014; McGowan, 2014), this is the ﬁrst experimental study that
simultaneously measured the respective drug concentrations in
multiple mucosal tissues to help correlate their values with those
seen in plasma. A recent study in rhesus macaques evaluated the
PK proﬁles of RAL after oral dosing (Massud et al., 2015). However,
the drug measurements were limited to that in plasma and
secretions in rectal and vaginal compartments, but not tissue
matrices. Also, the protective aspects (pharmacodynamics, PD)
were only studied ex vivo using rectal ﬂuids, in lieu of the mucosal
in vivo viral challenge. We have previously shown that oral
administration of RAL fully protected hu-mice from intravaginal
HIV-1 challenge (Neff et al., 2010). In this study we measured RAL
in blood plasma, vaginal, rectal and intestinal tissues, following
oral dosing and derived PK data. Our previous PK studies on
maraviroc and tenofovir with hu- and non-hu mice showed
notable differences (Veselinovic et al., 2014) and thus employing
hu-mice versus non-hu-mice is more ideal for correlating PK data
with that of PD studies in HIV PrEP.
Highest concentrations of RAL were detected at 2 h after last
dose in each of the compartments tested with a gradual decline up
to 24–48 h. The plasma Tmax of 2 h observed in hu-mice was
comparable to that seen in human studies (Markowitz et al., 2006;
Fig. 1. PK analysis of orally administered RAL in humanized mice. Mice were administered RAL by oral gavage (human equivalent dose 164 mg/kg) for 5 days. Post-last dose,
plasma and tissue samples were collected at different time points and drug concentrations were determined (ng/ml or ng/g). A. Composite medians and interquartile ranges
(IQR) for plasma, vaginal, rectal and intestinal tissue (colon). B–E. Individual data points (n¼5–8) for plasma (B), vaginal (C), rectal (D) and intestinal tissue (colon) (E) with
composite medians (IQR). Dotted line represents RAL in vitro 95% inhibitory concentration (IC95) of 33 nM (14.6 ng/ml).
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Fayet Mello et al., 2011). Variability in plasma drug concentrations
as seen in human studies was also observed in hu-mice with CV%
of 84% at 8 h and 150% at 24 h and 48 h (Supplementary Table 1)
(Markowitz et al., 2006; Cattaneo et al., 2012, 2012; Fayet Mello et
al., 2011; Rizk et al., 2012; Sandkovsky et al., 2012; Siccardi et al.,
2012). This is not likely due to the levels of human cell recon-
stitutions in hu-mice since mice with similar human cell levels
were used. The RAL plasma concentrations in hu-mice were above
the established in vitro IC95 of 33 nM (14.6 ng/ml) in all mice at 2 h
and 8 h, with a decline to lower levels in half of the mice by 24 h.
With regard to tissues, the overall drug exposure determined by
AUC24hr for RAL in vaginal tissue was 5 fold higher than in blood
plasma and 7 fold and 25 fold higher in rectal and intestinal tis-
sues, respectively. This was further illustrated by the tissue:
plasma AUC24h ratios (T:P ratio) (Fig. 2), which were 6.0, 8.5 and29.0 for vaginal, rectal and intestinal tissues respectively, con-
ﬁrming signiﬁcantly higher drug exposure in vaginal and rectal
tissues relative to plasma.
Among the important attributes for a promising PrEP drug
candidate are, high mucosal tissue penetration and retention over
time. Our results showed high RAL penetration into vaginal tissue
compared to plasma with the AUC24h tissue:plasma ratio of 6.
Previous human studies in HIV-1 infected and uninfected women
showed high RAL exposure with a CVF:plasma AUC ratio ranging
from 2–4 (Clavel et al., 2011; Patterson et al., 2010). Patterson et al
also observed high RAL exposure in 3 sites within the gastro-
intestinal tract, with plasma: tissue ratios ranging from 156 to 659
(Patterson et al., 2013). Similar high RAL penetration was seen in
our study in rectal and intestinal tissues. This higher and differ-
ential accumulation in various tissues compared to plasma akin to
that seen in human studies may be attributable to several factors
Fig. 2. Tissue to blood plasma RAL AUC24h ratios in humanized mice. Tissue to
plasma ratios were calculated for AUC24h. On the y axis 1 indicates a line of unity
where mucosal tissue exposure is similar to blood plasma. Values above the line of
unity indicate higher drug exposure at mucosal sites compared to plasma. VT-
vaginal tissue, RT-rectal tissue, IT-intestinal tissue (colon).
Table 1
PK parameters for Raltegravir in humanized mice.
RAL (hu-mice) Plasma Vaginal tissue Rectal tissue Intestinal tissue
Cmax
a 283 (123–
321)
3440 (731–
9349)
1213 (677–
2981)
11,692 (878–
32,332)
Ctrough
b 3.6 3.2 5.5 16.6
Tmax 2 h 2 h 2 h 2 h
AUC c 5510 28,172 39,742 135,610
t½
d 3.5 3.3 3.5 2.8
AUC24h T:P
Ratioe
/ 6.0 8.5 29.0
a Median (inter-quartile range, IQR) - ng/ml or ng/g.
b Geometric mean of all values at 24h post-last dose – ng/ml or ng/g.
c Area under the curve - AUC48h for plasma (ng*h/ml); AUC24h for tissues
(ng*h/g).
d Half-life (h) – 24 h.
e AUC24h tissue to plasma ratio.
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of drug transporters in distinct mucosal compartments (Nicol
et al., 2013; Hu et al., 2015).
The propensity of RAL for tissue penetration meets the criteria
for its use as a PrEP agent. However, due to its faster elimination
rate compared to other drugs (such as intracellular active meta-
bolite of tenofovir, tenofovir diphosphate) more frequent dosing or
higher daily dosing may be required to achieve reliable protection.
From a practical ﬁeld perspective wherein multiple HIV-1 strains
circulate with varied levels of drug resistance, deploying a single
agent such as RAL will be inadequate to confer full protection in a
global setting. Thus, a compatible combination of RAL and other
antiretrovirals with different mechanisms of action may be needed
for complete efﬁcacy.
In summary, we have derived comprehensive PK data on RAL in
plasma and multiple mucosal tissues to correlate with our pre-
vious PD study in hu-mice and compare these with human data
(Neff et al., 2010). Similar PK–PD studies can now be conducted to
derive preclinical data on new candidate ARTs in the pipeline to
help achieve rapid progress in the PrEP arena.Materials and methods
Generation of humanized mice
Humanized BALB/c-Rag1–/–γc–/– and BALB/c-Rag2–/–γc–/– (RAG-
hu) mice were generated using human CD34þ hematopoietic
progenitor cells as previously described (Akkina et al., 2011; Berges
et al., 2010, 2008, 2006). Mice were maintained at the Colorado
State University Painter Animal Center and all studies have been
reviewed and approved by the CSU Institutional Animal Care and
Use Committee (Protocol 11-3153A). Newborn mice were injected
intrahepatically with 0.5–1106 human CD34þ cells after being
preconditioned by irradiating with a sublethal dose of 350 rads.
Human cell engraftment was analyzed at 10–12 weeks post-
reconstitution. Peripheral blood was collected by tail bleed and
Whole Blood Erythrocyte Lysing Kit (R&D Systems, Minneapolis,
MN) was used for red blood cell lysis. The white blood cell fraction
was stained against the human pan-leukocyte marker CD45
(hCD45-R-PE, Invitrogen) and FACS analyzed to determine the
level of human cell engraftment. Mice with more than 50% human
cell engraftment were included in the study, to ensure good level
of humanization in mucosal tissues.Drug administration of anti-retrovirals and sample collection
Female mice were administered RAL by oral gavage. The clinical
formulation of the tablet (Isentresss: 400 mg, Merck & Co.) was
freshly dissolved in sterile PBS prior to oral gavage. The mouse
equivalent dose was calculated by using an interspecies allometric
scaling factor of 12.3 (Stoddart et al., 2007; Freireich et al., 1966).
Mice received RAL (3.28 mg per 20 g mouse) by oral gavage daily
for 5 days. This dosing was same as we used in our previous PD
study on RAL to determine its HIV prevention efﬁcacy (Neff et al.,
2010). Initial experiment included 5 mice per time point. Addi-
tional mice (2–3) were tested for the time points and compart-
ments for which RAL concentration was below limit of quantiﬁ-
cation or showed high degree of variability in the initial study.
Plasma and vaginal, rectal and intestinal tissue samples were
collected following the last gavage at 2 h, 8 h, and 24 h. In addi-
tion, 48 h plasma samples were collected from one group of
treated animals. All samples except 48 h blood plasma were
terminal and were collected during mouse necropsies. Tissue and
plasma samples were snap frozen in liquid nitrogen within ﬁve
minutes from the time of collection. For negative controls, plasma
and tissue samples were collected from untreated mice and were
processed using the protocols described above. All samples were
stored at 80 °C prior to drug concentration analysis.
Measurement of drug concentrations in plasma and tissue samples
Quantiﬁcation of analytes was similar to previously published
methods (Patterson et al., 2011). RAL was extracted from the
matrices by protein precipitation and quantiﬁed by LC–MS/MS
analysis. Plasma samples were mixed with methanol containing
the isotopically-labeled internal standards (2H RAL). Following
vortex and centrifugation, the supernatant was removed and
evaporated to dryness. The extracts were reconstituted with 1 mM
ammonium phosphate prior to LC–MS/MS analysis. RAL was
eluted from a Phenomenex Synergi Polar-RP (504.6 mm2, 4 mm
particle size) analytical column. An API-5000 triple quadrupole
mass spectrometer (AB Sciex, Foster City, CA) was used to detect
the analytes. Data were collected using AB Sciex Analyst Chro-
matography Software (Analyst version 1.6.1). The dynamic range of
this assay was 1–1000 ng/mL for each compound using a 1/
concentration2 weighted linear regression. Tissues were homo-
genized in 70:30 acetonitrile: 1 mM ammonium phosphate and
RAL in the resulting homogenate was extracted by protein pre-
cipitation with acetonitrile containing isotopically-labeled internal
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supernatant was removed and evaporated to dryness. Samples
were analyzed in a similar fashion to plasma. The drug levels
detected in tissue matrices reﬂect the combination of both extra-
and intracellular concentrations. The dynamic range of this assay
was 0.3–300 ng/mL of homogenate.
Pharmacokinetic and statistical analysis
Pharmacokinetic analysis was performed with Phoenix Win-
Nonlin Pro 5.2 (Certara, L.P., St. Louis MO) and GraphPad Prism
version 5 (GraphPad Software Inc., La Jolla, CA). Median maximal
concentration (Cmax), time to maximal concentration (Tmax), geo-
metric mean concentration at 24 h (Ctrough), as well as geometric
mean concentration and coefﬁcients of variation (CV%) for all time
points and compartments were determined in GraphPad Prism.
Measures of central tendency were expressed as composite med-
ian and inter-quartile range (IQR 25th, 75th percentile). The log-
linear trapezoidal method was used to calculate area under the
48 h (plasma) or 24 h (tissues) time/concentration curve (AUC48h
or AUC24h). The AUC tissue to plasma ratios were calculated using
AUC24h for plasma and tissue compartments. The half-lives (t1/2)
were determined with Phoenix WinNonlin using the median
composite PK proﬁle. Only data points determined to occur in the
beta-elimination phase through visual inspection were included in
the half-life calculation. PK data in hu and non-hu mice were
compared using Mann–Whitney two-tailed test. P values o0.05
were considered as signiﬁcant.Acknowledgments
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